ticagrelor

(redirected from Brilinta)
Also found in: Dictionary.

ticagrelor

(tye-ka-grel-or) ,

Brilinta

(trade name)

Classification

Therapeutic: antiplatelet agents
Pharmacologic: platelet aggregation inhibitors
Pregnancy Category: C

Indications

To decrease the incidence of thrombotic cardiovascular events associated with acute coronary syndrome (ACS).

Action

Both parent drug and its active metabolite inhibit platelet aggregation by reversibly interacting with platelet P2Y12ADP-receptors, preventing signal transduction and platelet activation.

Therapeutic effects

Reduced sequelae of ACS including cardiovascular death, MI and stroke.

Pharmacokinetics

Absorption: 36% absorbed following oral administration.
Distribution: Unknown.
Protein Binding: 99% for ticagrelor and its active metabolite.
Metabolism and Excretion: Mostly metabolized in the liver (CYP3A4 enzyme system, some metabolism by CYP3A5) with conversion to an active metabolite (AR-C124910XX); excretion primarily via biliary secretion; <1% excreted unchanged or as active metabolite in urine.
Half-life: Ticagrelor—7 hr; Active metabolite—9 hr.

Time/action profile (inhibition of platelet aggregation)

ROUTEONSETPEAKDURATION
POwithin 30 min4 hr5 days†
† Following discontinuation.

Contraindications/Precautions

Contraindicated in: HypersensitivityActive bleeding;History of intracranial bleeding;Severe hepatic impairment (increased risk of bleeding);Impending coronary artery bypass graft (CABG) surgery or other surgery (discontinue 5 days prior); Lactation: Avoid breast feeding;Strong inhibitors/inducers of CYP3A enzyme system (avoid concurrent use if possible).
Use Cautiously in: Moderate hepatic impairment (consider risks of increased levels);Hypotension following recent CABG or percutaneous coronary intervention (PCI) in patients receiving ticagrelor (consider bleeding as a cause); Geriatric: Some elderly patients may be more sensitive to effects; Obstetric: Use only during pregnancy if potential maternal benefit justifies potential risk to fetus; Pediatric: Safe and effective use has not been established.

Adverse Reactions/Side Effects

Cardiovascular

  • bradycardia

Respiratory

  • dyspnea (most frequent)

Endocrinologic

  • gynecomastia

Hematologic

  • bleeding (life-threatening)

Miscellaneous

  • hypersensitivity reactions including angioedema (life-threatening)

Interactions

Drug-Drug interaction

Strong inhibitors of CYP3A4/5 including atazanavir, clarithromycin, indinavir, intraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole ↑ levels and the risk of bleeding and should be avoided.Potent inducers of CYP3A including carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin may ↓ levels and effectiveness and should be avoided.Concurrent use of lovastatin or simvastatin in doses >40 mg/day ↑ risk of statin-related adverse reactions.Effectiveness is ↓ by aspirin >100 mg/day (maintain aspirin at 75–100 mg/day).May alter digoxin levels (monitoring recommended).Risk of bleeding ↑ by anticoagulants, fibrinolytics and chronic NSAIDs.

Route/Dosage

Oral (Adults) Loading dose—180 mg ; followed by maintenance dose—90 mg twice daily.

Availability

Tablets : 90 mg

Nursing implications

Nursing assessment

  • Assess patient for symptoms of stroke, peripheral vascular disease, or MI periodically during therapy.
  • Observe patient for signs and symptoms of hypersensitivity reactions (rash, facial swelling, pruritus, laryngeal edema, wheezing). Discontinue drug and notify health care professional immediately if symptoms occur. Keep epinephrine, an antihistamine, and resuscitation equipment close by in case of anaphylactic reaction.
  • Lab Test Considerations: May cause ↑ serum uric acid and ↑ serum creatinine.

Potential Nursing Diagnoses

Risk for injury (Adverse Reactions)

Implementation

  • Administer 180 mg (two 90 mg tablets) as a loading dose, followed by 90 mg twice daily. After initial 325 mg loading dose of aspirin, administer maintenance dose of 75–100 mg daily. Administer without regard for food.
    • Patients who have received a loading dose of clopidogrel may be started on ticagrelor.
    • Discontinue ticagrelor 5 days before planned surgical procedures. If ticagrelor must be temporarily discontinued, restart as soon as possible. Premature discontinuation of therapy may increase risk of myocardial infarction, stent thrombosis, and death.

Patient/Family Teaching

  • Instruct patient to take ticagrelor exactly as directed. Take missed doses as soon as possible unless almost time for next dose; do not double doses. Do not discontinue ticagrelor without consulting health care professional; may increase risk of cardiovascular events. Advise patient to read the Medication Guide before starting therapy and with each Rx refill in case of changes.
  • Advise patient that daily aspirin should not exceed 100 mg and to avoid taking other medications that contain aspirin.
  • Inform patient that they will bleed and bruise more easily and it will take longer to stop bleeding. Advise patient to notify health care professional promptly if unusual, prolonged, or excessive bleeding or blood in stool or urine occurs.
  • Inform patient that ticagrelor may cause shortness of breath which usually resolved during therapy. Advise patient to notify health care professional if unexpected or severe shortness of breath or symptoms of hypersensitivity reactions occur.
  • Advise patient to notify health care professional of medication regimen prior to treatment or surgery or dental procedure. Prescriber should be consulted before stopping ticagrelor.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications, especially aspirin or NSAIDs.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

  • Decreased thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
Mentioned in ?
References in periodicals archive ?
English-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca's heart drug, Brilinta, has failed to demonstrate a benefit over a generic blood thinner in patients with peripheral artery disease, it was reported yesterday.
It evaluated the treatment of Brilinta 90mg tablets twice daily versus clopidogrel 75mg once daily for the prevention of atherothrombotic events (a composite of cardiovascular death, heart attack or ischaemic stroke).
One of the main international clinical studies compared Brilinta to Plavix in 18,624 patients who were being treated for a blocked artery or heart attack.
Danske Markets sees a bigger possibility that the US authorities will approve AstraZeneca's experimental blood thinner Brilinta on 20 July 2011.
AstraZeneca followed close behind after lifting its full-year earnings guidance and gaining a boost for heart drug Brilinta from US regulators.
M2 PHARMA-September 30, 2015-AstraZeneca unveils BRILINTA (ticagrelor) 60-mg tablets in US pharmacies for long-term use in patients with a history of heart attack
M2 EQUITYBITES-September 30, 2015-AstraZeneca unveils BRILINTA (ticagrelor) 60-mg tablets in US pharmacies for long-term use in patients with a history of heart attack
AstraZeneca was downgraded by a broker who cut its sales forecast for the Brilinta and Crestor treatments.
On Monday, UBS set a "short-term buy" rating on AstraZeneca ahead of 20 July 2011, when the US authorities are due to decide on its experimental blood thinner Brilinta.
The company was recently boosted by news that trials of a new blood thinning pill, Brilinta had produced a 16% drop in heart attack and stroke deaths.